Moomoo AIのまとめ
Avalo Therapeutics, Inc. announced on June 24, 2024, the appointment of Paul Varki as the company's new Chief Legal Officer. Varki, aged 52, brings over two decades of legal experience in the pharmaceutical industry to Avalo Therapeutics. His previous roles include General Counsel at Idorsia Pharmaceuticals US Inc., Vice President of Legal at Amarin Corporation plc, and senior legal positions at Braeburn Pharmaceuticals and Egalet Pharmaceuticals. Varki's extensive background also includes various legal roles at GlaxoSmithKline and practice in FDA regulatory law. His academic credentials include a J.D. from Temple University School of Law, a Master of Public Health from George Washington University, and a Bachelor of Arts from the College of William and Mary. Alongside his appointment, Varki entered into an employment agreement with Avalo Therapeutics, which includes a base salary, potential bonuses, and equity incentives. The agreement also outlines severance benefits and restrictive covenants. Avalo Therapeutics is a clinical-stage biotechnology company focusing on immune dysregulation treatments, with AVTX-009 as its lead asset targeting inflammatory diseases.
Avalo Therapeutics, Inc. announced on June 24, 2024, the appointment of Paul Varki as the company's new Chief Legal Officer. Varki, aged 52, brings over two decades of legal experience in the pharmaceutical industry to Avalo Therapeutics. His previous roles include General Counsel at Idorsia Pharmaceuticals US Inc., Vice President of Legal at Amarin Corporation plc, and senior legal positions at Braeburn Pharmaceuticals and Egalet Pharmaceuticals. Varki's extensive background also includes various legal roles at GlaxoSmithKline and practice in FDA regulatory law. His academic credentials include a J.D. from Temple University School of Law, a Master of Public Health from George Washington University, and a Bachelor of Arts from the College of William and Mary. Alongside his appointment, Varki entered into an employment agreement with Avalo Therapeutics, which includes a base salary, potential bonuses, and equity incentives. The agreement also outlines severance benefits and restrictive covenants. Avalo Therapeutics is a clinical-stage biotechnology company focusing on immune dysregulation treatments, with AVTX-009 as its lead asset targeting inflammatory diseases.
Avalo Therapeutics, Inc.は2024年6月24日に、Paul Varki氏を同社の新しい最高法務責任者に任命したことを発表しました。52歳のVarki氏は、医薬品業界で20年以上の法務経験をAvalo Therapeuticsにもたらします。以前の役職には、Idorsia Pharmaceuticals US Inc.の総法務顧問、Amarin Corporation plcの法務副社長、Braeburn PharmaceuticalsおよびEgalet Pharmaceuticalsでの上級法務ポジションが含まれます。Varki氏の広範なバックグラウンドには、Glaxo...すべて展開
Avalo Therapeutics, Inc.は2024年6月24日に、Paul Varki氏を同社の新しい最高法務責任者に任命したことを発表しました。52歳のVarki氏は、医薬品業界で20年以上の法務経験をAvalo Therapeuticsにもたらします。以前の役職には、Idorsia Pharmaceuticals US Inc.の総法務顧問、Amarin Corporation plcの法務副社長、Braeburn PharmaceuticalsおよびEgalet Pharmaceuticalsでの上級法務ポジションが含まれます。Varki氏の広範なバックグラウンドには、GlaxoSmithKlineの様々な法務ポジションやFDA規制法の業務経験も含まれます。 彼の学歴は、Temple University School of LawのJ.D.、George Washington Universityの公衆衛生修士、College of William and Maryの文学士が含まれます。Varki氏は、Avalo Therapeuticsとの雇用契約にも署名し、基本給、ボーナスの可能性、株式のインセンティブが含まれています。 契約には解雇手当や制限的結束事項も記載されています。 Avalo Therapeuticsは、免疫調節治療に焦点を当てた臨床段階のバイオテクノロジー企業であり、AVTX-009は炎症性疾患をターゲットとするリードアセットです。
役に立った
役に立たない